Safest treatment of hyperthyroidism in pregnant women is:
The core concept here is knowing which antithyroid drug is safest in different trimesters. I remember that PTU is preferred in the first trimester because methimazole has been associated with a higher risk of fetal malformations, especially a syndrome called choanal atresia. However, in the second and third trimesters, methimazole might be preferred over PTU because PTU can cross the placenta more and might cause hepatotoxicity in the mother. Also, radioactive iodine is absolutely contraindicated in pregnancy because it can damage the fetal thyroid.
Now, the correct answer should be Propylthiouracil (PTU) for the first trimester. The options might include other drugs like methimazole, radioactive iodine, or maybe beta-blockers. Beta-blockers are used to manage symptoms but don't treat the underlying hyperthyroidism. Radioactive iodine is definitely not safe. Surgery is a last resort.
For the wrong options: Methimazole (Option B) is linked to fetal malformations in the first trimester. Radioactive iodine (Option C) is contraindicated during pregnancy. Beta-blockers (Option D) don't treat the hyperthyroidism, just control symptoms.
Clinical pearl: Remember that PTU is first-line in the first trimester, then switch to methimazole in the second and third. Also, radioactive iodine is a big no-no during pregnancy. Make sure to mention that beta-blockers are for symptom control, not as a primary treatment. High-yield fact: PTU in first trimester, methimazole later, avoid radioactive iodine.
**Core Concept**
Hyperthyroidism during pregnancy requires careful management to avoid fetal and maternal complications. The primary treatment is antithyroid drugs (ATDs), with **propylthiouracil (PTU)** preferred in the first trimester due to its lower risk of fetal malformations compared to methimazole.
**Why the Correct Answer is Right**
**Propylthiouracil (PTU)** is the safest antithyroid medication in the **first trimester** of pregnancy because it crosses the placenta less than methimazole, reducing the risk of fetal **choanal atresia** and other congenital anomalies. PTU also inhibits the peripheral conversion of thyroxine (T4) to triiodothyronine (T3), providing additional therapeutic benefit. However, PTU is associated with hepatotoxicity, so it is typically switched to **methimazole** in the **second and third trimesters**, where its placental transfer is lower and fetal risk is reduced.
**Why Each Wrong Option is Incorrect**
**Option A: Methimazole** β Linked to fetal **choanal atresia** and limb defects in the first trimester, making it contraindicated early in pregnancy